On the other hand, compounds targeting TYK2 JH2 have been shown to efficiently inhibit TYK2-mediated signaling and are in phase 3 clinical trials against autoimmune diseases (Figure 3C) [132,133]). This evidence concerns the gene TYK2 and autoimmune disease.